Welcome to our dedicated page for Gelstat news (Ticker: GSAC), a resource for investors and traders seeking the latest updates and insights on Gelstat stock.
GelStat Corporation reports developments tied to its transition into engineered solutions for industrial security through its subsidiary GSAC Engineering. Company news has centered on the iCAS, or Intelligent Correctional Facilities Automation Systems, platform; acquired software, engineering designs and operating processes; and service contracts for secure government-operated facilities.
Earlier updates also covered GelStat's development-stage consumer healthcare products, Regulation A+ financing, capital restructuring and share-recovery actions. More recent releases focus on recurring security monitoring services, infrastructure support and the subsidiary's deployment of proprietary technology in medium- to high-security environments.
Summary not available.
GelStat Corporation (OTCPink: GSAC) has launched GSAC Engineering, a new division aimed at driving corporate growth as part of its turnaround plan. This initiative focuses on developing technology for industrial security and renewable energy. The company intends to secure intellectual property to enhance its competitive edge and is negotiating contracts with medium-tier security facilities in the southeastern U.S. CEO Javier Acosta expressed optimism about the new division's potential in shaping GelStat's future growth.
GelStat Corporation (OTCPink: GSAC) announced updates regarding its capital market activities, including a planned Regulation A+, Tier 2 equity financing of up to $5 million. The company has recouped over 100 million shares of common stock, which will enhance its treasury for future issuance. Outstanding shares have increased to approximately 618 million. CEO Javier Acosta indicated that these actions are aimed at simplifying the capital structure and pursuing growth. GelStat focuses on marketing non-prescription health products such as Migraine and Sleep formulations.
GelStat Corporation (OTCPink: GSAC) has received SEC qualification for a Regulation A+ public offering, aiming to raise up to $5 million. This funding will support marketing and the development of its OTC health products, including a homeopathic migraine solution and the reintroduction of its sleep product. The offering circular is available on the company's OTC Markets profile. CEO Javier Acosta emphasized the company's progress in restoring its status in the financial markets, focusing on product innovation in the multibillion-dollar health supplement sector.